Cargando…
Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes
Heart failure with reduced ejection fraction (HFrEF) is increasingly treated with medications for type 2 diabetes mellitus (T2DM). Whether metabolic derangements in HFrEF and T2DM are associated with differential outcomes remains unclear. Therefore, understanding molecular pathways in HFrEF and T2DM...
Autores principales: | Lerman, Joseph B., Giamberardino, Stephanie N., Hernandez, Adrian F., Felker, G. Michael, Shah, Svati H., McGarrah, Robert W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163122/ https://www.ncbi.nlm.nih.gov/pubmed/35654972 http://dx.doi.org/10.1038/s41598-022-12973-0 |
Ejemplares similares
-
Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
por: Hunter, Wynn G., et al.
Publicado: (2016) -
Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy
por: Truby, Lauren K., et al.
Publicado: (2021) -
Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
por: Salah, Husam M., et al.
Publicado: (2021) -
Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation
por: Ahn, Min-Soo, et al.
Publicado: (2021) -
Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
por: Peters, Anthony E., et al.
Publicado: (2021)